Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 1/20 | 0.30 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25729639 | 0.96 | KDM4E (0.43) | CES2KDM4EALDH1A1GAAPOLB | |
| SCHEMBL23664671 | 0.96 | KDM4E (0.43) | CES2KDM4EALDH1A1GAAPOLB | |
| SCHEMBL22024176 | 0.87 | KDM4E (0.39) | CES2KDM4EALDH1A1GAAMEN1 | |
| SCHEMBL26849925 | 0.86 | CES2 (0.53) | CES2KDM4EALDH1A1GAAPOLB | |
| SCHEMBL19069268 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL20223175 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL4547565 | 0.82 | KDM4E (0.38) | CES2KDM4EALDH1A1GAAPOLB | |
| SCHEMBL5831101 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL22932423 | 0.80 | KDM4E (0.47) | KDM4EALDH1A1GAAPOLBMEN1 | |
| SCHEMBL20133152 | 0.79 | KDM4E (0.43) | CES2KDM4EALDH1A1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| US-9695170-B2 | Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160159796-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | CES2 131/4885KDM4E 4122/4885ALDH1A1 2370/4885 |
| US-20160159796-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | CES2 3248/4885KDM4E 943/4885ALDH1A1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.